Premium
Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia
Author(s) -
Ghannam Jack,
Dillon Laura W.,
Hourigan Christopher S.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16362
Subject(s) - myeloid leukaemia , minimal residual disease , medicine , dna sequencing , residual , computational biology , immunology , leukemia , biology , gene , genetics , computer science , algorithm
Summary Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic mutations. There is great interest in accurately establishing measurable residual disease (MRD) burden in AML patients in remission after treatment but at risk of relapse. However, inter‐ and intrapatient genetic diversity means that, unlike in the chronic myeloid and acute promyelocytic leukaemias, no single genetic abnormality is pathognomonic for all cases of AML MRD. Next‐generation sequencing offers the opportunity to test broadly and deeply for potential genetic evidence of residual AML, and while not currently accepted for such use clinically, is likely to be increasingly used for AML MRD testing in the future.